Literature DB >> 26417344

The rediscovery of HepG2 cells for prediction of drug induced liver injury (DILI).

Ahmed Ghallab1.   

Abstract

Entities:  

Year:  2014        PMID: 26417344      PMCID: PMC4464501     

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


× No keyword cloud information.

In the past HepG2 cells have been considered to show only little similarity to primary human hepatocytes (Godoy et al., 2013[8]; Hewitt et al., 2007[12]). However, recently it has become clear that the phenotype of HepG2 cells strongly depends on culture conditions. In a recent study, Ramaiahgari et al. (2014[21]) cultivated HepG2 cells in spheroids. In this culture system the cells stopped proliferation and strongly upregulated phase I and phase II drug metabolizing enzymes and transporters (Ramaiahgari et al., 2014[21]). Moreover, albumin and urea metabolizing enzymes were upregulated. This study shows that the potential of HepG2 cells may have been underestimated in the past. A critical aspect seems to be that they have to be kept in three dimensional culture systems. Much effort has been invested in the establishment of hepatocyte culture systems that help to identify hepatotoxic compounds (Ilkavets, 2013[14]; Abdelhamid et al., 2013[1]; Vinken et al., 2013[26]; Hasmall et al., 2001[9]; Waterfield et al., 1998[28]; Mennes et al., 1994[19]; Krijt et al., 1993[15]; Godoy et al., 2009[7]; Adler et al., 2014[2]; Maruf and O’Brien, 2014[18]). In recent years HepG2 cells have become more and more popular for this purpose (Mostafavi-Pour et al., 2013[20]; Shan et al., 2013[22]; Krithika et al. 2013[16]; Doricakova et al., 2013[6]; Straser et al. 2011[23]; Dias da Silva et al., 2013[3]; Horinouchi et al., 2014[13]; Wang et al., 2014[27]). One reason for their frequent application may be that they are freely available in contrast to some other cell lines obtained from human liver tumors that are only commercially available. Another successful application of HepG2 cells is expression of human genes (Lahoz et al., 2013[17]). The group of Castell and Gomez-Lechon have specialized in this field (Tolosa et al., 2012[24]; Donato et al., 2010[4]; 2008[5]). Recently, five P450 enzymes have been expressed simultaneously in HepG2 cells resulting in a powerful test system for compounds that require metabolic activation (Tolosa et al., 2013[25]). It is clear that primary human hepatocytes currently still represent the gold standard for hepatotoxicity testing (Hengstler et al., 2000[11]; 2009[10]; Hewitt et al., 2007[12]). Future studies will have to show to which degree HepG2 based culture system can be used to predict hepatotoxic compounds in vitro.
  28 in total

Review 1.  Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.

Authors:  Nicola J Hewitt; María José Gómez Lechón; J Brian Houston; David Hallifax; Hayley S Brown; Patrick Maurel; J Gerald Kenna; Lena Gustavsson; Christina Lohmann; Christian Skonberg; Andre Guillouzo; Gregor Tuschl; Albert P Li; Edward LeCluyse; Geny M M Groothuis; Jan G Hengstler
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

2.  Free radical generation from an aniline derivative in HepG2 cells: a possible captodative effect.

Authors:  Yuya Horinouchi; Fiona A Summers; Marilyn Ehrenshaft; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2014-11-05       Impact factor: 7.376

3.  Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway.

Authors:  Yajun Wang; Jun Wu; Biyun Lin; Xv Li; Haitao Zhang; Hang Ding; Xiaoyi Chen; Liubo Lan; Hui Luo
Journal:  Toxicology       Date:  2014-09-28       Impact factor: 4.221

4.  Antioxidative and cytoprotective effects of andrographolide against CCl4-induced hepatotoxicity in HepG2 cells.

Authors:  R Krithika; R J Verma; P S Shrivastav
Journal:  Hum Exp Toxicol       Date:  2012-09-27       Impact factor: 2.903

5.  Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis.

Authors:  Patricio Godoy; Jan G Hengstler; Iryna Ilkavets; Christoph Meyer; Anastasia Bachmann; Alexandra Müller; Gregor Tuschl; Stefan O Mueller; Steven Dooley
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

6.  An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors.

Authors:  Agustín Lahoz; Maya R Vilà; Myriam Fabre; Josep M Miquel; Manuel Rivas; Jessica Maines; José V Castell; M José Gómez-Lechón
Journal:  Toxicol In Vitro       Date:  2012-08-13       Impact factor: 3.500

7.  HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.

Authors:  Laia Tolosa; M José Gómez-Lechón; Gabriela Pérez-Cataldo; José V Castell; M Teresa Donato
Journal:  Arch Toxicol       Date:  2013-02-09       Impact factor: 5.153

Review 8.  Cell lines: a tool for in vitro drug metabolism studies.

Authors:  M T Donato; A Lahoz; J V Castell; M J Gómez-Lechón
Journal:  Curr Drug Metab       Date:  2008-01       Impact factor: 3.731

9.  Enhanced cytotoxicity of pentachlorophenol by perfluorooctane sulfonate or perfluorooctanoic acid in HepG2 cells.

Authors:  Guoqiang Shan; Minqiang Ye; Benzhan Zhu; Lingyan Zhu
Journal:  Chemosphere       Date:  2013-08-22       Impact factor: 7.086

10.  Flutamide-induced cytotoxicity and oxidative stress in an in vitro rat hepatocyte system.

Authors:  Abdullah Al Maruf; Peter O'Brien
Journal:  Oxid Med Cell Longev       Date:  2014-10-13       Impact factor: 6.543

View more
  5 in total

1.  Therapy of hyperammonemia.

Authors:  Agata Widera
Journal:  EXCLI J       Date:  2015-12-22       Impact factor: 4.068

2.  Highlight report: New methods for quantification of bile canalicular dynamics.

Authors:  Ahmed Ghallab
Journal:  EXCLI J       Date:  2015-12-21       Impact factor: 4.068

3.  Transcriptomic signature for drug-induced steatosis.

Authors:  Regina Stöber
Journal:  EXCLI J       Date:  2015-12-21       Impact factor: 4.068

4.  Highlight report: Interspecies extrapolation by physiologically based pharmacokinetic modeling.

Authors:  Agata Widera
Journal:  EXCLI J       Date:  2015-09-01       Impact factor: 4.068

5.  Highlight report: Blueprint for stem cell differentiation into liver cells.

Authors:  Ahmed Ghallab
Journal:  EXCLI J       Date:  2015-09-02       Impact factor: 4.068

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.